Cancer Research Horizons has joined Lifebit’s Federated Data Network to help maximise the impact of data generated through Cancer Research UK-funded research.
This federated network leverages Lifebit’s cutting-edge Platform to ensure secure access to standardised datasets of millions of cancer patients from multiple international institutions for use in secure, large-scale cross-cohort analyses.
The Antibody Series is a leading conference bringing together experts in the field of antibody discovery and development across Industry, Academia and Investment.
The annual event attracts more than 300 invited global leaders across biotech, pharmaceutical, venture capital, and academic sectors and is co-joined by over 4,000 registered participants from the scientific community online.
Find out more about 𝐛𝐢𝐨𝐚𝐧𝐚𝐥𝐲𝐭𝐢𝐜𝐚𝐥 𝐚𝐬𝐬𝐚𝐲𝐬 in our upcoming webinar scheduled for Thursday, February 27 at 8am PT/11am ET/4pm GMT.
Join experts Hermes Licea-Perez, Jing Lai and Scott Summerfield who will be discussing the analytical challenges associated with the LC-MS bioanalysis of low molecular weight molecules (<200 amu) often associated with metabolomic measurements and analysis of biomarkers and metabolic products of drug biotransformations.
By registering once, you will have access to and receive updates for each webinar in the series.
The upcoming BCA Spring Meeting will focus on the theme “Learning from Others”, emphasizing the importance of collaboration in the current research environment to interact and work together to get the best data or to develop a deeper understanding of science.
The field of Crystallography supports research across various disciplines, and this will be celebrated at the upcoming Spring Meeting.
Plenary Speakers:
- John Helliwell (University of Manchester)
- Lucia Maini (University of Bologna)
- Robert Palgrave (UCL)
- Elton Zeqiraj (University of Leeds)
AMSBIO has launched MatriMix for PDX, a fully defined extracellular matrix (ECM) hydrogel comprising of collagen, laminin-511 E8 fragments and hyaluronic acid optimized to support patient-derived xenograft (PDX) studies.
Life sciences dealmaking volume is stable, but value is down. The 2025 edition of the EY Firepower report explores how life sciences companies can secure a more confident future with smarter, smaller deals.
Key takeaways from the EY 2025 Firepower analysis:
RSM UK’s co-leads of life sciences, Laragh Jeanroy and Graham Bond, highlight three key themes dominating the sector in 2025:
Tighter funding
The value of private equity (PE) buyouts in the UK life sciences sector jumped from £778m in 2023 to £5.3bn in 2024, according to Pitchbook. However, the number of deals has remained fairly steady over the years, increasing from 10 in 2023 to 13 in 2024. A large proportion of PE and venture capital investment in the sector focused on traditional pharmaceuticals last year.
Cancer Research UK, Cytovation and the Norwegian Cancer Society have signed an agreement to bring Cytovation’s lead asset, CY-101, into a multi-national Phase 2 clinical trial for patients with adrenocortical carcinoma (ACC).
This rare and aggressive cancer, which affects the adrenal glands, has limited treatment options and an urgent need for new therapies.
London, January 23, 2025 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully completed a search assignment for NeoPhore Limited and is pleased to announce the placement of Michael Shih as Chief Executive Officer (CEO) and Board of Director.
https://www.globenewswire.com/news-release/2025/01/22/3013431/0/en/Cond…
Conduit Pharmaceuticals Partners with Agility Life Sciences to Create Enhanced Formulations for its Autoimmune Pipeline
• Award winning Agility Life Sciences brings a proven track record in drug formulation for a number of pharmaceutical and biotechnology clients.